To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.

SIGNUP

Already Have an Account?

Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Vol:230 Issue:1 Number:2 ISSN#:2564-2537
DOWNLOAD ESPAÑOL
RCT
ACE Report #14539
Ace Report Cover Shoulder & Elbow

AAOS 2022: Opioid-Sparing Pain Management Protocol After Shoulder Arthroplasty


How to Cite

OrthoEvidence. AAOS 2022: Opioid-Sparing Pain Management Protocol After Shoulder Arthroplasty. ACE Report. 2022;230(1):2. Available from: https://myorthoevidence.com/AceReport/Report/14539

Study Type:Randomized Trial
OE Level Evidence:N/A
Journal Level of Evidence:N/A

Opioid-Sparing Pain Management Protocol following Shoulder Arthroplasty Results in Less Opioid Consumption and Higher Satisfaction: A Prospective, Randomized Control Trial

Contributing Authors:
TJ Brolin CA Jones JA Murphy RR Eason M Joyce D Bernholt FM Azar TW Throckmorton

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

CONFERENCE ACE REPORTS

This ACE Report is a summary of a conference presentation or abstract. The information provided has limited the ability to provide an accurate assessment of the risk of bias or the overall quality. Please interpret the results with caution as trials may be in progress and select results may have been presented.

Synopsis

A total of 78 patients were included in this randomized trial comparing an opioid-sparing and opioid-based pain protocol for pain management after total shoulder arthroplasty. Outcomes of interest included pain scores, opioid consumption, patient satisfaction, range of motion, patient-reported functional outcomes, complications, readmission and reoperation. Results revealed significantly lower opi...

Ace Report Preview Image
CME Image

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.

LEARN MORE
For Reprints and Permissions, click here

Please Login or Join to leave comments.